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Abstract
4T1 metastatic breast cancer model have been widely used to study stage IV human breast
cancer. However, the frequent inoculation of a large number of cells, gives rise to fast grow-
ing tumors, as well as to a surprisingly low metastatic take rate. The present work aimed at
establishing the conditions enabling high metastatic take rate of the triple-negative murine
4T1 syngeneic breast cancer model. An 87% 4T1 tumor incidence was observed when as
few as 500 cancer cells were implanted. 4T1 cancer cells colonized primarily the lungs with
100% efficiency, and distant lesions were also commonly identified in the mesentery and
pancreas. The drastic reduction of the number of inoculated cells resulted in increased
tumor doubling times and decreased specific growth rates, following a Gompertzian tumor
expansion. The established conditions for the 4T1 mouse model were further validated in a
therapeutic study with peguilated liposomal doxorubicin, in clinical used in the setting of
metastatic breast cancer. Inoculated cell density was proven to be a key methodological
aspect towards the reproducible development of macrometastases in the 4T1 mouse
model and a more reliable pre-clinical assessment of antimetastatic therapies.
Introduction
The manifestation of metastases is predictive of poor clinical outcome [1–4], and prevails one
of the most challenging issues faced by cancer treatment today. A continuous effort in dissect-
ing the biological processes behind cancer cell dissemination has been pushing forward our
understanding of the disease and uncovering vulnerabilities that may be exploited for the
development of novel agents to treat metastatic cancer.
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Mouse models are crucial to our comprehensive knowledge on the molecular basis and
pathogenesis of cancer disease [5]. Nevertheless, a major impediment for the study of metasta-
ses has been the unavailability of suitable mouse models that accurately recapitulate the com-
plexity of human tumor progression [6, 7]. To better mimic the development of metastases in
humans, several parameters need to be considered in a mouse model, namely location and
implantation method of the primary tumor, interaction of cancer cells with the microenviron-
ment at the primary and secondary sites, dissemination routes and time-to-progression of the
disease. Subcutaneous transplantation of human (xenograft) and murine (allograft) cell lines
into mice, and genetic engineeredmice, are widely used for the establishment of pre-clinical
models [6, 8]. In the subcutaneousmodel, ectopic location of cancer cells usually fails to pro-
duce metastases, owing to the limited tumor microenvironment generated [9]. Furthermore,
surgical resection of primary tumors is often imperative in order to prolong mice survival and
enable the development of spontaneous metastases [6]. Genetic engineeredmouse models sur-
pass some of these constrains, offering the possibility of orthotopic neoplastic generation in
immune competent hosts [6, 8]. Nevertheless, metastatic lesions may appear only upon long
latency periods and generally their incidence is low [6, 8]. Even though the existing pre-clinical
models still offer valuable information about the biology, molecular basis and therapeutic
opportunities, the setting up of spontaneous metastases faces several challenges, and improve-
ment of its modeling remains of major importance [6, 7, 10].
The murine 4T1 breast carcinoma cell line has remarkable tumorigenic and invasive charac-
teristics. Upon injection in the mammary gland of BALB/c mice, 4T1 cells spontaneously gen-
erate tumors and are described to metastasize to the lungs, liver, lymph nodes, brain and
bones, in a way that closely resembles human breast cancer [11]. Owing to its characteristics,
4T1 cells have been widely used to study stage IV human breast cancer [12–15]. Moreover, 4T1
murine tumors represent a clinically relevant triple-negative breast cancer model [16–18],
which, alongside the cancer cell invasion and metastization, is an important challenge due to
its lack of responsiveness to endocrine therapy. However, 4T1 metastatic breast cancer model
suffers from the liability of fast growing tumors enhanced by the frequent inoculation of a large
number of cells, rendering a tumor microenvironment that does not recapitulate human breast
tumors, early mice euthanasia [15, 19–25], along with a surprisingly low metastatic take rate.
2Notwithstanding the widespread use of the 4T1 animal model, some of the aforemen-
tioned issues truly limit its usefulness to understand the biology of metastatic breast cancer
and therefore the identification of novel therapeutic opportunities and the corresponding
proof of concept. The need of translatable and predictive tumor models is a recognized need
for successful drug development. The present work aimed at establishing the conditions
enabling high metastatic take rate of the widespread triple-negative murine 4T1 syngeneic
breast cancer model, towards a more reliable pre-clinical screening of anticancer drugs. It
was demonstrated that the significant reduction of 4T1 cancer cell density implanted ortho-
topically, is a key methodological aspect underlying the reproducible development of macro-
metastases in this mouse model.
Materials and Methods
Ethics statement
All animal experiments were conducted according to human standards of animal care (2010/
63/EU directive and Portuguese Act 113/2013, for the use of experimental animals), and
approved by the corresponding national authority (Direção Geral de Alimentação e Veteri-
nária). Animals were euthanized by cervical dislocation.
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Materials
Ethylenediaminetetraacetic acid disodium salt dihydrate, potassium phosphate monobasic,
disodiumphosphate anhydrous, potassium chloride and sodium chloride were purchase from
Sigma-Aldrich (USA). Caelyx1 was kindly provided by the Pharmacy of the University Hos-
pital of Coimbra (Portugal).
Cell culture
4T1 [19, 26] (ATCC1 CRL-2539™, USA) mycoplasma-free cells were cultured in RPMI-1640
(Sigma-Aldrich,USA) supplemented with 10% (v/v) heat-inactivated Fetal Bovine Serum
(Invitrogen, USA), 100 U/ml penicilin, 100 μg/ml streptomycin (Lonza, Switzerland) and
maintained at 37°C in a 5% CO2 atmosphere.
In vivo experiments
Cell suspensions were prepared at 5 x 103, 2 x 104, 5 x 105 and 10 x 106 cells/mL in phosphate-
buffered solution, and maintained at room temperature. Five to six weeks old Balb/c female
mice (Balb/cAnNCrl) were orthotopically inoculatedwithin 40 min after preparation of cell
suspension, in the fourth inguinal mammary fat pad (100 μL/mouse).
For the cell titration, mice were assigned to different groups according to the number of 4T1
cells to be injected: 500, 2000, 5 x 104 and 1 x 106. Tumor volume was measured with a caliper
every other day, and determined based on the equation π/6(a x b2), where a is the largest
tumor diameter and b is the smallest [27]. Tumors were allowed to grow between 100–200
mm3 or> 250 mm3, after which animals were euthanized for necropsy and organs harvested
for histological analysis.
For the therapeutic study, mice were orthotopically inoculatedwith 500 4T1 cancer cells per
mouse. Mice bearing 100–150 mm3 tumors were intravenously treated with Caelyx1 at 5 mg
doxorubicin/kg body weight/week, for five weeks. An additional group was injected with
saline.
The development of clinical signs of distress caused by the metastatic disease and body
weight losses higher than 20% were not consented and were reason for animal euthanasia.
Upon necropsy, the organs were removed, weighed and processed for histological analysis.
All animal experiments were conducted according to human standards of animal care
(2010/63/EU directive and Portuguese Act 113/2013, for the use of experimental animals).
Relative tumor volume, metastatic incidence and metastatic burden
Mean relative tumor volume was expressed as the percentage of the ratio between the tumor
volume in each time point and at the beginning of the treatment. Metastatic incidence was
determined by the ratio between the number of mice that developedmetastases, upon histolog-
ical confirmation, and the total number of mice assessed. The weight of the lungs was used as a
measure of the metastatic burden in this organ, as extensively reported by others [28–31] and
confirmed by us, upon comparing non-tumor- or tumor-bearingmice, with or without treat-
ment with Caelyx1 (S1 Fig). Relative weight of the organs was expressed as percentage of
body weight at the time of death.
Tumor growth curves
Exponential and Gompertzmathematical models [32] were fit to the mean tumor volume data
(overtime) of all mice using non-linear regression, and goodness-of-fit of the models was com-
pared through the Akaike’s Information Criteria (AIC) values and the extra sum-of-squares F
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test. Specific growth rate (SGR) and doubling time (DT) were determined and given in the out-
put of the fitting analysis.
Histological analysis of primary tumors and metastases
Primary tumors and organs were kept on fixative solution (Tissue-Tek1 Xpress1 Molecular
Fixative, Sakura) for 24 h, after which tissues were paraffin embedded, sectioned onto slides
(4 μm) and stained with hematoxylin/eosin (H&E) or mouse anti-CD31 monoclonal antibody
(clone JC70, pre-diluted ref. n° 760–4378, Ventana Medical Systems, Inc., USA) using the
BenchMark ULTRA IHC/ISH staining module (Ventana Medical Systems, Inc., USA). Mean
vascular density was the mean of CD31 stained blood vessels counted in 4 different fields
(400x) of a primary tumor section.
H&E stained sections were visualized in a Axioskop 2 Plus microscope (Zeiss, Germany) for
the histological evaluation of metastases and primary tumors invasion of surrounding tissues.
Viable rim area was determined in the entire section by excluding necrotic areas, and repre-
sented as a ratio of the total area of that section, analyzed with the Fiji software (Life-Line ver-
sion, 2014 November 25, NIH, USA).
Statistical analysis
Data were analyzed using unpaired nonparametric one-way ANOVA, followed by Dunn’s mul-
tiple comparisons test, except when only two groups were compared, in which case unpaired
nonparametricMann-Whitney test was applied. Viable rim area and vessel density for different
tumor sizes were analyzed using unmatched two-way ANOVA with Tukey’s multiple compari-
sons test. Log-rank test was applied for the survival curves and metastatic incidence in the ther-
apeutic study was analyzed with a two-tailed chi-square test. All the analyses were performed
with a 95% confidence interval.
Results
Metastatic pattern and efficiency
The 4T1 metastatic breast carcinoma model is amply used. However, a large number of cells
are often implanted in mice [15, 19–24] and require primary tumor removal to extend the dis-
ease time course, besides presenting a low metastatic efficiency. Herein, we assessed the effect
of inoculated 4T1 cell density on the metastatic efficiency, without removal of the primary
tumor. Immunocompetent Balb/c female mice were orthotopically injectedwith four cell den-
sities, ranging from 500 to 1 x 106 cells, and tumor incidence, time for tumor onset, and meta-
static efficiencywere evaluated.
No obvious correlation was detected between tumor incidence and the inoculated 4T1 cell
density (Table 1). The percentage of mice that developed breast carcinomas varied from 85%
to 92%, in animals implanted with 5 x 104 and 1x106 cells, respectively. However, the mean
time for tumor onset was significantly different between the groups inoculated. Palpable
tumors were detected at 17.5 and 16.5 d post injection of 500 and 2000 cancer cells, respec-
tively, whereas this latency time drastically decreasedwhen 5 x 104 (7.6 d, p< 0.01) or 1 x 106
(3.6 d, p< 0.0001) 4T1 cells were implanted (Table 1).
The time course of primary tumor growth might have implications on its metastatic effi-
ciency. In fact, the number of mice with detectable lung metastases significantly increased in
those groups with the longest tumor onset, achieving 100% efficacyon the group where only
500 cells were inoculated (Table 1). In contrast, only 45% of mice developed lung metastases
(or metastatic nodules in other tissues), for cell densities superior to 5 x 104. As the endpoint of
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this experiment was a similar primary tumor burden across the four groups (p = 0.1938), the
time elapsed from cell inoculation to animals sacrificewas significantly reduced in the groups
injectedwith 5 x 104 and 1 x 106 4T1 cells (Table 1). In these experimental conditions, the met-
astatic process was more efficient when lower numbers of 4T1 cells were inoculated.Nonethe-
less, the observeddifferences in the metastatic efficiencywill likely be attenuated if the animals
inoculatedwith higher cell densities were allowed to live longer (a condition that would be
associated with higher tumor burdens).
Fig 1 shows representative images of 4T1 breast tumors and metastatic lesions in several tis-
sues. The highly invasive nature of these tumors was confirmed by their capacity to invade
neighboringmammary parenchyma (Fig 1A–1C), muscle fibers (Fig 1D) and adjacent skin
(Fig 1E and 1F). Macrometastatic lesions in several organs and tissues were also observed (Fig
1G–1K). In these experiments, 4T1 cells have colonizedmainly the lungs (Fig 1G), as previ-
ously described [19, 33], while macrometastases in the liver were rarely observed.As impor-
tant, macrometastases in the brain were not identified.Metastases in tissues such as the
mesentery (Fig 1H) and pancreas (Fig 1I) were often observed, and occasionally in lymphatic
nodes (Fig 1J). Less frequently, other tissues, like the salivary gland (Fig 1K), were affected.
However, the extent of pulmonary and visceral lesions was considerably variable amongst indi-
viduals. Different metastatic patterns were observed in mice, particularly on the lowest cell
densities: either small lesions extensively spread, or scarce but larger metastatic nodules. There-
fore, it was difficult to establish the metastatic burden based on the number or volume of the
lesions. Moreover, it was difficult to performweight estimates in certain tissues, such as the
mesentery.
Dynamics of 4T1 tumor growth
Dynamics of tumor growth were analyzed by two mathematical models commonly used to
describe tumor growth: the Exponential and Gompertzmodels [34]. The first is a simplistic
model that assumes that the number of cancer cells doubles during cell cycle, resulting in expo-
nential growth of solid tumors. However, tumor growth involves other biological processes,
such as regulation of proliferation, stromal recruitment, escape from immunesurveillanceand
angiogenesis, thereby being usually explained by the Gompertz model, which considers growth
rate decay as tumors become larger [35, 36]. Tumor growth curves fitted to the experimental
mean tumor volumes over time are presented in Fig 2A. The model providing the best fit was
chosen based on Akaike’s information criteria and extra sum-of-squares F test (Fig 2B) analysis
[37, 38].
Table 1. Tumor growth and metastases in 4T1 breast carcinoma-bearing mice.
No. 4T1 cells
inoculated
No. of mice with
tumors/total
mice (%)
Mean tumor onset (days
until palpable
tumors ± SEM)
Time from inoculation to
euthanasia
(days ± SEM)
Mean tumor volume at
euthanasia (mm3 ±
SEM)
No. of mice with detectable
lung metastases/no. of mice
evaluated (%)
1x106 11/12 (92%) 3.6 ± 2.54 a 18.4 ± 1.26 a 229.5 ± 45.82 5/11 (45%)
5x104 11/13 (85%) 7.6 ± 0.84 b 24.9 ± 2.28 a 210.6 ± 31.44 5/11 (45%)
2000 13/15 (87%) 16.5 ± 1.05 35.4 ± 1.65 285.9 ± 44.35 7/9 (78%)
500 13/15 (87%) 17.5 ± 0.91 37.0 ± 2.08 318.1 ± 34.05 7/7 (100%) c
a p < 0.0001.
b p < 0.01 relative to 500 and 2000 cell densities (nonparametric one-way ANOVA with Dunn’s multiple comparisons test).
c p = 0.0167, relative to 5x104 and 1x106 cell densities (two-tailed chi-square test).
doi:10.1371/journal.pone.0165817.t001
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Tumor growth showed a Gompertz behavior for all groups, except for those generated from
inoculation of 1x106 cells, where exponential growth was prevalent (Fig 2). Notwithstanding,
Gompertzian tumor growth was diverse among the different groups. It was evident that tumors
generated from 5 x 104 cells attained the decay phase much earlier than the tumors resulting
from the inoculation of lower cell densities (Fig 2A).
Doubling time and specific growth rate, two parameters usually used to quantify and char-
acterize neoplastic growth, were also determined.One million and 5 x 104 cell density groups
averaged growth rates of 14.9% and 16.1% per day, with doubling times of 4.6 and 4.3 days,
respectively (Fig 2B).
Fig 1. Representative sections from orthotopic 4T1 tumors and nodular metastatic deposits. Tumor cells
invading the surrounding mammary parenchyma (A—C), muscle fibers (D) and adjoining skin (E–F) show the highly
invasive capacity of 4T1 breast tumors. Examples of metastatic lesions were observed in the lungs (G), mesentery
(H), pancreas (I) lymph nodes (J), or salivary gland (K). MP, mammary parenchyma; MF, muscle fibers; S, skin; LP,
lung parenchyma; LN, lymph node; MES, mesentery; PC, pancreas; SG, salivary gland; * indicates tumor areas. All
images present original magnification x200, except upper left and inset images, x50.
doi:10.1371/journal.pone.0165817.g001
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4T1 tumors viable rim area and vasculature
Tumor necrosis is thought to result from rapidly proliferating cancer cells outpacing their
blood supply in certain tumor regions [39, 40]. As necrotic cells release pro-inflammatory fac-
tors into the tumor microenvironment, which are known to promote tumor growth and dis-
semination [39, 41], it was further questioned whether the altered dynamics would affect the
viable rim area and vascular density of primary tumors, and whether it would relate to their
metastatic efficiency. Sections from tumors of all groups were stained either with H&E, to
Fig 2. Fitting mathematical growth models to tumor experimental data as a function of inoculated cell
density. Exponential and Gompertz models were fitted to the population’s tumor growth curves (A) and compared
using the Akaike’s information criteria (AIC) and the extra sum-of-squares F test (B). Specific growth rates (SGR) and
doubling times of each group were determined from the mathematical equations of the best fit (B). Dark symbols
represent experimental mean tumor volumes. The solid line represents the best fit for each group with a 95%
confidence interval, light lines.
doi:10.1371/journal.pone.0165817.g002
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determine the viable rim area, or with CD31, to assess vascular density. Additionally, the analysis
accounted for differences on tumor volumes, distinguishing between smaller (100–200 mm3)
and larger (> 250 mm3) tumors, within each group of mice. Both the viable rim area and vascular
density were independent from tumor volume and cell density inoculated (Fig 3A and 3B, respec-
tively). Representative images of tumor sections stained with CD31 (Fig 3C) confirmed the high
vascularizednature of these tumors, regardless the number of inoculated cells they were gener-
ated from. These tumors already entailed a good vascular network at volumes between 100–150
mm3.
Overall, neither the viable rim area nor the vascular density of tumors originating from the
different cell densities correlated with their respectivemetastatic efficiency. Nevertheless, the
inoculation of 500 4T1 cancer cells provided the best metastatic efficiency, possibly due to
lower specific growth rates (or extended doubling times), yielding an optimal model to study
metastatic breast cancer.
Validation of the established conditions for the 4T1 metastatic breast
cancer mouse model
In order to validate the previously characterized 4T1 metastatic breast carcinoma mouse
model, a therapeutic study was conducted with pegylated liposomal doxorubicin (Caelyx1), a
cytotoxic agent used in the clinical setting of metastatic breast cancer.
Fig 3. Effect of cell density and tumor mean volume on viable rim area and vascular density.
Quantitative analysis of viable rim area (A) and vascular density (B) was assessed in tumors with mean
volumes of 100–200 mm3 and > 250 mm3, based on H&E or CD31 immunostaining in carcinoma sections
derived from 500, 2000, 5 x 104 and 1 x 106 cancer cells, original magnification x400 (C). Data represent the
mean ± SEM of 3–6 independent sections. ns, p > 0.05 two-way ANOVA with Tukey’s multiple comparisons
test.
doi:10.1371/journal.pone.0165817.g003
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Upon inoculation of 500 4T1 cancer cells in the mammary fat pad, Balb/c mice were mon-
itored for body weight and symptoms of distress caused by metastatic disease [42, 43]. In
view of the preceding results, therapeutic protocol was initiated when tumors presented an
established vascular network (100–150 mm3). Mice were weekly treated via the lateral tail
vein with Caelyx1, at 5 mg doxorubicin/kg body, for 5 weeks, and a control group was
injected with saline. Due to widespread of metastatic disease, not all animals completed this
therapeutic regimen. The majority of mice in the control group survived up to the 3rd dose,
and only those treated with Caelyx1 managed to achieve the 5th administration. A signifi-
cant reduction of the primary tumor was observed in three Caelyx1-treated mice, although
followed by regrowth, as well as two complete remissions (Fig 4A). The latter remained
tumor-free for more than 60 days after the last dose and did not present metastatic nodules
upon necropsy. Nevertheless, three animals responded poorly to the Caelyx1 therapy and
died from the disease (Fig 4B). Non-treated mice presented quite a different response,
namely in terms of primary tumor growth (p< 0.0001 relative to Caelyx-treated mice, Fig
4A) and overall survival (median 16 days versus 46 days in the Caelyx1-treated group, Fig
4B; Log-rank p = 0.0064.
Histological analysis of the neoplastic tissues confirmed the vast capacity of 4T1 breast
cancer cells to invade muscle, skin and surrounding mammary parenchyma (Fig 4C). Cae-
lyx1 did not limit tumoral invasiveness (Fig 4C), nor induced a significant reduction of
the viable rim area as compared to non-treated mice (Fig 4D). This effect was consistent
with the comparable mean vascular density (Fig 4E and 4F) observed between treatment
with Caelyx1 (287 ± 17.95 counts/mm2) and non-treated mice (332 ± 32.91 counts/mm2).
Secondarymetastatic lesions in several organs/tissues were also observed in all animals,
with the exception of the two mice that presented a complete response to Caelyx1
(Table 2).
One hundred percent of non-treated animals presented lung metastases. The incidence
decreased in the Caelyx1 cohort (75%) owing to disease remission in two mice. Noteworthy,
the results also pointed to a reduction of mesenteric nodules in mice under Caelyx1 therapy
compared to non-treated mice (38% versus 77%, p = 0.0708), with the contribution of the two
disease-freemice at the end of the experiment (Table 2). Despite lung metastatic burden of
non-treated animals (1.37 ± 0.12) was comparable to the one of Caelyx1 group (1.65 ± 0.31),
Fig 5, the latter presented the longest survival rate (Fig 4B). Notwithstanding the significant
effect of Caelyx1 on primary tumor growth inhibition, the extended survival time of these ani-
mals enabled a sufficient time frame for metastatic development, already in site by the time of
treatment initiation.
Splenomegaly was confirmed by visual examination and relative organ weight quantifica-
tion, in all mice bearing 4T1 tumors compared to naïve animals (Fig 6A), in agreement with
data from other studies [33, 44]. Interestingly, treatments with Caelyx1 resulted in a slight
decrease of relative spleen weight, in comparison with non-treated mice (Fig 6A). Histological
examination of the spleens revealed hyperplasia of the red pulp with a concomitant reduction
of the white pulp, with particular emphasis in non-treated mice (Fig 6B), and consistent with
extramedullaryhematopoiesis.
Nonetheless, some degree of toxicity might have occurred given the increase of mean rela-
tive kidneys weight in Caelyx1-treated animals (p values = 0.0048), relative to non-treated
mice (Fig 6C). Symptoms of palmar-plantar erythrodysesthesiawere not registered in mice
treated with Caelyx1, in contrast with previous reports [45], possibly due to a lower dose of
doxorubicin used herein.
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Discussion
The orthotopic inoculation of cancer cells is extensively used in breast cancer research. The
predictive utility of these tumor models relies on their capacity to reproduce human malig-
nancy, and should allow the analysis of human primary tumor growth, including invasion of
Fig 4. Therapeutic activity of Caelyx® in 4T1 breast tumor-bearing mice. Balb/c mice implanted with
500 4T1 cancer cells in the mammary fat pad were treated weekly with Caelyx®, at 5 mg doxorubicin/kg
body weight for 5 weeks (indicated by grey arrows). An additional control group included non-treated mice
(injected with saline). Individual tumor growth curves (A) and survival curves (B) are illustrated. H&E staining,
original magnification x200 (C), quantification of viable rim area (D), CD31 immunostaining, original
magnification x400 (E), and quantification of vascular density (F), on representative sections from 4T1
primary tumors, following treatment either with Caelyx® or saline. MF, muscle fibers; S, skin; MP, mammary
parenchyma; * indicates tumor areas. Data represents individual relative tumor volumes and median survival
curves of saline- (n = 14) and Caelyx®-treated (n = 8) mice. Viable rim area and vascular density represent
mean ± SEM of 3 independent sections. ns, p > 0.05 two-tailed nonparametric Mann-Whitney test.
doi:10.1371/journal.pone.0165817.g004
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Table 2. Incidence of metastatic lesions in 4T1 breast carcinoma-bearing mice.
No. of mice with metastatic lesions /total no. of mice analyzed (%)
Lungs Liver Pancreas Mesentery Diaphragm
Control 13/13 (100%) 2/13 (15%) 9/13 (69%) 10/13 (77%) 6/13 (46%)
Caelyx® 6/8 (75%)a 0/8 (0%) 4/8 (50%) 3/8 (38%)b 2/8 (25%)
a, p = 0.0581.
b, p = 0.0708 (two-tailed chi-square test analysis).
doi:10.1371/journal.pone.0165817.t002
Fig 5. Metastatic burden in the lungs following treatment with Caelyx®. Metastatic burden was determined upon organ weight for individual
mice treated either with Caelyx® or saline, and further normalized for the whole body weight. Data represent individual (dots) or mean ± SEM of
control (n = 13) and Caelyx® (n = 6) mice. ns, p > 0.05 two-tailed nonparametric Mann-Whitney test.
doi:10.1371/journal.pone.0165817.g005
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surrounding tissue, interactions of tumor cells with their stromal components, and metastatic
progression [6, 8]. Breast cancer originates from genetic and epigenetic transformations in a
single cell, progressing to clonal expansion and selection and, ultimately, to metastatic disease
[46]. Animal models of breast cancer have provided some understanding of these features,
enabling the proposal of new treatments [47]. However, primary breast tumors often originate
from the inoculation of a large number of cancer cells, which is associated with a high growth
rate, failing to efficiently generate metastases or leading to their surgically resection to prolong
survival [6]. Therefore, this strategy clearly deviates from the natural history of the disease,
resulting in neoplastic tissues that, from our experience, do not resemble the human malig-
nancy. Likewise, the 4T1 breast carcinoma mouse model is frequently implemented upon inoc-
ulation of a large number of 4T1 cancer cells in the mammary fat pad of mice, ranging from 1 x
104 to more than 1x106 cells [15, 19–25]. However, in the present work it has been demon-
strated that the inoculation of such high cell densities compromised the development of an effi-
cient and reproducible model of spontaneous metastases.
It was demonstrated that 4T1 tumors grew orthotopically when as few as 500 cancer cells
were inoculated, being tumor incidence comparable for cell densities ranging from 500 to
1x106 (87% and 92%, respectively). However, inoculated cell density influenced significantly
the latency period for first palpation and metastatic efficiency (Table 1). The indirect correla-
tion between the number of inoculated cancer cells and the time required to proliferate and
generate a larger tumor mass, was in contrast with the effect on the metastatic efficiency. Only
45% of mice inoculatedwith 1x106 cells presented macroscopic secondary lesions, which is in
contrast with the 100%metastatic efficiencyof the group inoculatedwith 500 cells (Table 1).
Interestingly, Bailey-Down et al. [48] also showed that reducing the number of implanted 4T1
Fig 6. Effect of Caelyx® in the spleen and kidneys of mice bearing 4T1 tumors. Relative weight (A) and
representative H&E images, original magnification x50 (left) or x200 (right) (B) of spleens from naive mice
and mice treated with Caelyx® or saline (control). Images illustrate the red pulp markedly expanded by
numerous hematopoietic cells (black arrowheads), including megakaryocytes (black arrows), and myeloid
precursor cells, particularly in the controls. Red circles represent white pulp areas with lymphoid nodules.
The relative weight of kidneys (C) from Caelyx®- or saline-treated control mice was also analyzed. ***,
p < 0.001, nonparametric one-way ANOVA with Dunn’s multiple comparisons test; **, p < 0.01, two-tailed
nonparametric Mann-Whitney test.
doi:10.1371/journal.pone.0165817.g006
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cells increasedmetastatic efficiency. Nevertheless, in animals inoculatedwith a cell density
equal or lower than 1500, the tumor take rate was lower than 50% and macrometastases were
barely observed at five weeks post-implantation [48], in contrast with results reported herein.
In the work of Bailey-Down et al., the best compromise between tumor take rate (over 90%)
and metastatic efficiency (67% in the lungs) was achieved upon inoculation of 7500 4T1 cells.
It is well known that the shedding of cancer cells into the bloodstream is an early event in the
process of tumorigenesis [49, 50]. Therefore, one could assume that tumors originated from
different cell densities would enable similar metastatic potential. However, in the groups inocu-
lated with the highest cell densities, the time frame between tumor onset and animal euthanasia
was strongly shortened by the high tumor burden and subsequent need of primary tumor
resection. This short time frame was not sufficient for the progression of seeded cells into
macrometastases. Therefore, the present results clearly demonstrated that the inoculation of
low cell densities surpass the need of primary tumor resection, thus becoming a key methodo-
logical aspect to the reproducible development of macrometastases in the 4T1 mouse model.
The results herein presented also highlighted the impact of cancer cell density on the
dynamics of the primary tumor development, as reflected by the different growth curves, and
specific growth rates and doubling times (Fig 2). In fact, tumors originated from 5x104 and
1x106 cells grew at a rate approximately 2 and 3 times faster than those from 2000 and 500 cell
densities, respectively, being in line with the corresponding shortened time for tumor onset
(Table 1). Two conceptual theories, the Exponential [34] and Gompertz [34, 35] growth mod-
els, have been used to describe the tumor dynamics. The first one states that primary tumor
expansion is purely the result of cell division, resulting in exponential growth of solid tumors,
while the second incorporates different growth rates, depending on the stage of tumor develop-
ment [35]. The cancer cell inoculation titration herein performedwas better describedby the
Gompertzmodel, but only to a certain extent, as tumors generated from 1x106 cells followed
an exponential growth. An old concept to explain the Gompertzmodel is the insufficient nutri-
ent supply to large solid tumors, which impairs their unlimited expansion [51], thus justifying
the decrease of growth rate upon reaching a certainmean volume. Yet, evidence of large tumors
(1–2 cm3) with an adequate vascular network [52] has challenged this theory, and is in agree-
ment with the results obtained herein showing similar mean vascular densities (Fig 3B) and
viable rim areas (Fig 3A), regardless tumor burden and inoculated cell densities. More recently,
the idea of self-seeding [36] as a multidirectional process, whereby cancer cells seed secondary
sites and re-infiltrate the primary foci, has been validated in several experimentalmodels,
including the 4T1 breast cancer model [53]. Self-seeding selects for highly aggressive fractions
of circulating tumor cells based on their movement and survival in the bloodstream.The pri-
mary tumor homing of this population of cells was shown to further induce angiogenesis and
invasion, in addition to the breeding of metastatic progenies in a compatible soil [53]. This pro-
cess is thought to contribute for the Gompertzian expansion of tumors [36] and might be also
contributing for the high metastatic efficiencyobserved for the lowest 4T1 cell densities.
The higher metastatic efficiencyof the 500, 2000 and 5x104 cell density groups may result
from other factors as well. 4T1 cancer cells were shown to play an active role in the production
and release of a variety of chemokines [44, 54–57] that stimulate hematopoiesis, enabling the
recruitment and activation of inflammatory cells to the primary tumors and metastatic lesions,
and modulation of the endothelial function [33, 44, 58–60]. Among the inflammatory cells
infiltrating the 4T1 tumors, a CD11b+ myeloid population with the F4/80+CD11c+ Gr-1+ phe-
notype was the most prominent, increasing over time, in parallel with tumor growth, while
lymphoid cells decreased [44]. Although we did not look into systemic and microenvironment
local changes, the occurrence of splenomegaly was observed, suggesting that a leukemoid reac-
tion took place (Fig 6A and 6B). duPré and Hunter have previously correlated splenomegaly in
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the 4T1 tumor-bearingmice with a prominent increase in immature splenic granulocytes,
along with a reversal of the splenic lymphocyte:granulocyte ratio, with decreased percentages
of B- and T-cells [56]. Waight et al. further confirmed a marked increase in splenic CD11b
+Gr-1+ cells of 4T1 tumor-bearingmice in response to granulocyte colony-stimulating factor
(G-CSF) [61]. These events stimulated primary foci progression and, ultimately, metastasiza-
tion by promoting cancer cell invasion, dissemination, seeding and growth into metastatic
lesions [56, 61–63]. Nevertheless, all these processes require a minimum time frame to occur.
As such, the time frame requested for the expansion of seeded cells into macrometastases could
explain the lower metastatic efficiencyof 5x104 cell inoculated group, as compared to the 500
and 2000 counterparts, despite all follow the Gompertz growth model.
In the therapeutic study, no physical signs of toxicity were attained by treatment with Cae-
lyx1, albeit kidneys enlargement was observed in these mice (Fig 6C). Although Caelyx1 was
not proficient in fully preventing metastatic disease (Table 2), it enabled a significant therapeu-
tic response (Fig 4A and 4B). The reduction of primary tumor burden promoted by Caelyx1
was a major contributor for the observedmedian overall survival, and reduced the metastatic
incidence in the mesentery (Table 2). The antitumor efficacyof Caelyx1 in animal models is
the result of the enhanced permeability and retention (EPR) effect, to which the high circula-
tion half-life in the blood and subsequent passive extravasation at the level of the leaky tumor
blood vessels have a major contribution [64–66]. Therefore, the presence of an established vas-
culature is essential for the therapeutic activity of Caelyx1. The absence of a vascular network
or the existence of a poorly developed vasculature in lung metastases, as compared to the pri-
mary tumor, may justify the high metastatic burden despite treatment with Caelyx1. Never-
theless, and since colonization of the visceral organs by cancer cells in the 4T1 mammary
carcinoma model was described to occur later than the lungs [19, 33, 48], it is possible that the
liposomal chemotherapy tested herein, limited further dissemination/colonization of tissues of
the peritoneal cavity by 4T1 cells, accounting for a lower incidence of metastasis in the mesen-
tery. Extramedullaryhematopoiesis has been shown to play a crucial role in the spontaneous
metastization in the 4T1 mouse model [44, 56], by contributing to a receptive microenviron-
ment for circulating tumor cells arrest, survival and proliferation in the lungs [44, 67, 68].
Therefore, the therapeutic activity of Caelyx1 could be partially exerted by restricting splenic
hematopoiesis, as reflected in a reduced splenomegaly, relative to non-treated mice (Fig 6A
and 6B). Likewise, it has been demonstrated in mouse models of glicosarcoma, neuroblastoma
and lung cancer [69, 70] that Caelyx1 exerted its antitumoral activity in part by the ability to
elicit an antivascular effect. This effect was not observedherein with the 4T1 model, possibly
due to the aggressiveness of the cancer model used herein and/or dose scheduling. The low
extent of the antivascular effectmight support the similar tumor viable rim area betweenmice
treated with Caelyx1 and non-treated mice (Fig 4D). Additionally, non-tumoral vessels from
surrounding tissues are also expected to provide nutrient and oxygen supplies to cancer cells
[71, 72]. These factors likely contributed to the maintenance of tumor viable areas that fuels its
expansion and invasion (Fig 4C), and could be responsible for the tumor regrowth observed in
some Caelyx1-treatedmice.
Conclusions
Notwithstanding the 4T1 mouse model being widely used to study metastatic breast cancer,
the low metastatic efficacy is barely mentioned in the literature. Herein, it was demonstrated
that reducing the number of 4T1 cancer cells implanted orthotopically, to a number as low as
500 cells, resulted both in a higher metastatic efficiency and primary tumor take rate, signifi-
cantly affecting the dynamics of tumor growth. This becomes a key methodological aspect
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towards the reproducible development of macrometastases in the 4T1 mouse model, as vali-
dated in the therapeutic experiment. Extending the time length of tumor development will
enable longitudinal studies to follow all the steps of cancer cell dissemination in the same indi-
vidual, as well as a better assessment of anti-metastatic therapies.
Supporting Information
S1 Fig. Metastatic burden in the lungs of non-tumor- or tumor-bearingmice, with or with-
out treatment with Caelyx1.Metastatic burden (A) was determined upon organ weight for
individual mice, either naïve, non-treated (control) or treated with Caelyx1. Representative
images of the lungs (B) from non-treated (control) or Caelyx1-treatedmice and their corre-
spondent weight. Relative lungs weight, in parentheses, was determined upon normalization
for the whole body weight. Data represented individual (dots) or mean ± SEM of naïve (n = 6),
control (n = 13) and Caelyx1 (n = 8) mice. , p< 0.01 non-parametric one-way ANOVA
with Dunn’s multiple comparisons test.
(PDF)
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44. DuPré SA, Redelman D, Hunter KW. The mouse mammary carcinoma 4T1: characterization of the cel-
lular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol. 2007; 88(5):351–60.
doi: 10.1111/j.1365-2613.2007.00539.x PMID: 17877537.
Inoculated Cell Density Is a Determinant Factor of Metastatic Efficiency
PLOS ONE | DOI:10.1371/journal.pone.0165817 November 7, 2016 17 / 19
45. Charrois GJR, Allen TM. Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics
and Therapeutic Activity. Journal of Pharmacology and Experimental Therapeutics. 2003; 306
(3):1058–67. doi: 10.1124/jpet.103.053413 PMID: 12808004
46. Polyak K. Breast cancer: origins and evolution. The Journal of clinical investigation. 2007; 117(117
(11)):3155–63. doi: 10.1172/JCI33295 PMID: 17975657
47. Singh M, Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.
Nature biotechnology. 2012; 30(7):648–57. doi: 10.1038/nbt.2286 PMID: 22781694
48. Bailey-Downs LC, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. Development and
characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic pro-
gression. PLoS One. 2014; 9(5):e98624. Epub 06/01. doi: 10.1371/journal.pone.0098624 eCollection
2014. PMID: 24878664.
49. Weng D, Penzner JH, Song B, Koido S, Calderwood SK, Gong J. Metastasis is an early event in
mouse mammary carcinomas and is associated with cells bearing stem cell markers. Breast Cancer
Research C7—R18. 2012; 14(1):1–13.
50. Psaila B, Lyden D. The Metastatic Niche: Adapting the Foreign Soil. Nature reviews Cancer. 2009; 9
(4):285–93. doi: 10.1038/nrc2621 PMID: 19308068
51. Burton AC. Rate of growth of solid tumours as a problem of diffusion. Growth. 1966; 30(2):157–76.
PMID: 5963695
52. Folkman J. What Is the Evidence That Tumors Are Angiogenesis Dependent? Journal of the National
Cancer Institute. 1990; 82(1):4–7. PMID: 1688381
53. Kim M-Y, Oskarsson T, Acharyya S, Nguyen DX, Zhang XHF, Norton L, et al. Tumor Self-Seeding by
Circulating Cancer Cells. 2009; 139(7):1315–26. doi: 10.1016/j.cell.2009.11.025 PMID: 20064377
54. Adler EP, Lemken CA, Katchen NS, Kurt RA. A dual role for tumor-derived chemokine RANTES
(CCL5). Immunology letters. 2003; 90(2):187–94.
55. Kurt RA, Baher A, Wisner KP, Tackitt S, Urba WJ. Chemokine receptor desensitization in tumor-bear-
ing mice. Cellular immunology. 2001; 207(2):81–8. doi: 10.1006/cimm.2000.1754 PMID: 11243697
56. duPré SA, Hunter KW Jr. Murine mammary carcinoma 4T1 induces a leukemoid reaction with spleno-
megaly: association with tumor-derived growth factors. Experimental and molecular pathology. 2007;
82(1):12–24. doi: 10.1016/j.yexmp.2006.06.007 PMID: 16919266
57. Vitiello PF, Shainheit MG, Allison EM, Adler EP, Kurt RA. Impact of tumor-derived CCL2 on T cell
effector function. Immunology letters. 2004; 91(2):239–45.
58. Huang Y, Ma C, Zhang Q, Ye J, Wang F, Zhang Y, et al. CD4+ and CD8+ T cells have opposing roles
in breast cancer progression and outcome. Oncotarget. 2015.
59. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer Associated Fibroblasts Promote Tumor
Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast
Cancer Model. PLoS ONE. 2009; 4(11):e7965. doi: 10.1371/journal.pone.0007965 PMID: 19956757
60. duPre SA, Redelman D, Hunter KW Jr. Microenvironment of the murine mammary carcinoma 4T1:
Endogenous IFN-γ affects tumor phenotype, growth, and metastasis. 2008; 85(3):174–88. doi: 10.
1016/j.yexmp.2008.05.002 PMID: 18929358
61. Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth
through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PloS one. 2011; 6(11):
e27690. doi: 10.1371/journal.pone.0027690 PMID: 22110722
62. Hanahan D, Coussens LM. Accessories to the Crime: Functions of Cells Recruited to the Tumor Micro-
environment. 2012; 21(3):309–22. doi: 10.1016/j.ccr.2012.02.022 PMID: 22439926
63. Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, et al. New horizons in tumor microenvironment biology:
challenges and opportunities. BMC Medicine C7–45. 2015; 13(1):1–14.
64. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of
tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation. 2001; 41(1):189–
207. http://dx.doi.org/10.1016/S0065-2571(00)00013-3. PMID: Maeda2001189.
65. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use
in solid tumors. Drugs. 1997; 54(4):15–21.
66. Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to
clinical applications. Journal of controlled release. 1998; 53(1):275–9.
67. Yokoi K, Tanei T, Kai M, Saito Y, Liu YT, Ferrari M. Abstract P1-07-13: Extramedullary hematopoiesis
aids initiation of cancer metastasis. Cancer Research. 2015; 75(9 Supplement):P1-07-13-P1-07-13.
doi: 10.1158/1538-7445.SABCS14-P1-07-13
Inoculated Cell Density Is a Determinant Factor of Metastatic Efficiency
PLOS ONE | DOI:10.1371/journal.pone.0165817 November 7, 2016 18 / 19
68. Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, Chytil A, et al. Gr-1+ CD11b+ myeloid cells tip the bal-
ance of immune protection to tumor promotion in the premetastatic lung. Cancer research. 2010; 70
(15):6139–49. doi: 10.1158/0008-5472.CAN-10-0706 PMID: 20631080
69. Zhou R, Mazurchuk R, Straubinger RM. Antivasculature Effects of Doxorubicin-containing Liposomes
in an Intracranial Rat Brain Tumor Model. Cancer Research. 2002; 62(9):2561–6. PMID: 11980650
70. Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, et al. Enhanced Antitumor Efficacy of
Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin. Clinical Cancer Research. 2008; 14
(22):7320–9. doi: 10.1158/1078-0432.CCR-08-0804 PMID: 19010847
71. Nguyen L, Fifis T, Malcontenti-Wilson C, Chan L, Costa PNL, Nikfarjam M, et al. Spatial morphological
and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent
treatments. BMC Cancer C7–522. 2012; 12(1):1–13.
72. Hori K, Akita H, Nonaka H, Sumiyoshi A, Taki Y. Prevention of cancer recurrence in tumor margins by
stopping microcirculation in the tumor and tumor–host interface. Cancer Science. 2014; 105(9):1196–
204. doi: 10.1111/cas.12477 PMID: 24981848
Inoculated Cell Density Is a Determinant Factor of Metastatic Efficiency
PLOS ONE | DOI:10.1371/journal.pone.0165817 November 7, 2016 19 / 19
